Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 19/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 13/20 | 0.45 |
| ▸ | ADORA1 | P30542 | 13/20 | 0.45 |
| ▸ | ADORA2B | P29275 | 12/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11968388 | 1.00 | ADORA2A (0.46) | ADORA2AADORA3ADORA1ADORA2B | |
| SCHEMBL11968389 | 1.00 | ADORA2A (0.46) | ADORA2AADORA3ADORA1ADORA2B | |
| SCHEMBL2806489 | 1.00 | ADORA2A (0.46) | ADORA2AADORA3ADORA1ADORA2B | |
| SCHEMBL2806491 | 1.00 | ADORA2A (0.46) | ADORA2AADORA3ADORA1ADORA2B | |
| SCHEMBL2807610 | 0.97 | ADORA2A (0.49) | ADORA2AADORA3ADORA1ADORA2B | |
| SCHEMBL2807606 | 0.97 | ADORA2A (0.49) | ADORA2AADORA3ADORA1ADORA2B | |
| SCHEMBL2807616 | 0.97 | ADORA2A (0.49) | ADORA2AADORA3ADORA1ADORA2B | |
| SCHEMBL2806547 | 0.95 | ADORA2A (0.51) | ADORA2AADORA3ADORA1ADORA2B | |
| SCHEMBL2806546 | 0.95 | ADORA2A (0.51) | ADORA2AADORA3ADORA1ADORA2B | |
| SCHEMBL12049797 | 0.95 | ADORA2A (0.51) | ADORA2AADORA3ADORA1ADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8435966-B2 | Associations of xanthogenates and cyclodextrins, and their use | BIOSPHINGS AG (DE) | 2013-05-07 | — | — | US | claimed |
| EP-2044070-B1 | PURINE DERIVATIVES AS A2A AGONISTS | NOVARTIS AG (CH) | 2012-08-22 | — | — | EP | claimed |
| US-8071565-B2 | Purine derivatives as a2a agonists | NOVARTIS AG (CH) | 2011-12-06 | — | — | US | claimed |
| US-20100240606-A1 | ASSOCIATIONS OF XANTHOGENATES AND CYCLODEXTRINS, AND THEIR USE | BIOSPHINGS AG (DE) | 2010-09-23 | — | — | US | claimed |
| EP-2001840-A1 | ASSOCIATIONS OF XANTHOGENATES AND CYCLODEXTRINS, AND THEIR USE | BioSphings AG (DE) | 2008-12-17 | — | — | EP | claimed |
| WO-2007112828-A1 | ASSOCIATIONS OF XANTHOGENATES AND CYCLODEXTRINS, AND THEIR USE | BIOSPHINGS AG (DE) | 2007-10-11 | — | — | WO | claimed |
| EP-3525886-B1 | COMPOSITIONS COMPRISING A METAL SOURCE, DITHIOCARBAMATE AND CYCLODEXTRIN | DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES OEFFENTLICHEN RECHTS / UNIV HEIDELBERG (DE) | 2022-02-23 | — | — | EP | disclosed |
| EP-3921647-A1 | IMPROVED DITHIOCARMABATE BASED COMPOUNDS, THERAPIES AND DIAGNOSTICS | Deutsches Krebsforschungszentrum - Stiftung des öffentlichen Rechts / Universität Heidelberg (DE) | 2021-12-15 | — | — | EP | disclosed |
| CN-113474660-A | Improved dithiocarbamate-based compounds, therapies and diagnostics | 德国癌症研究公共权益基金会 | 2021-10-01 | — | — | CN | disclosed |
| US-10953099-B2 | Compositions comprising a metal source, dithiocarbamate and cyclodextrin | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts (DE) | 2021-03-23 | — | — | US | disclosed |
| WO-2020161337-A1 | IMPROVED DITHIOCARMABATE BASED COMPOUNDS, THERAPIES AND DIAGNOSTICS | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts (DE) | 2020-08-13 | — | — | WO | disclosed |
| EP-3693740-A1 | IMPROVED DITHIOCARMABATE BASED COMPOUNDS, THERAPIES AND DIAGNOSTICS | Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts (DE) | 2020-08-12 | — | — | EP | disclosed |
| US-20190328886-A1 | COMPOSITIONS COMPRISING A METAL SOURCE, DITHIOCARBAMATE AND CYCLODEXTRIN | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts (DE) | 2019-10-31 | — | — | US | disclosed |
| US-20100240606-A1 | ASSOCIATIONS OF XANTHOGENATES AND CYCLODEXTRINS, AND THEIR USE | BIOSPHINGS AG (DE) | 2010-09-23 | — | — | US | disclosed |
| US-20100240680-A1 | Purine derivatives as a2a agonists | NOVARTIS AG (CH) | 2010-09-23 | — | — | US | disclosed |
| US-20100240680-A1 | Purine derivatives as a2a agonists | NOVARTIS AG (CH) | 2010-09-23 | — | — | US | disclosed |
| US-20100240680-A1 | Purine derivatives as a2a agonists | NOVARTIS AG (CH) | 2010-09-23 | — | — | US | disclosed |
| EP-2001840-A1 | ASSOCIATIONS OF XANTHOGENATES AND CYCLODEXTRINS, AND THEIR USE | BioSphings AG (DE) | 2008-12-17 | — | — | EP | disclosed |
| EP-1889846-A1 | Purine derivatives as A2a agonists | Novartis AG (CH) | 2008-02-20 | — | — | EP | disclosed |
| WO-2007112828-A1 | ASSOCIATIONS OF XANTHOGENATES AND CYCLODEXTRINS, AND THEIR USE | BIOSPHINGS AG (DE) | 2007-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10953099-B2 | Compositions comprising a metal source, dithiocarbamate and cyclodextrin | PDIA5, SLC30A5, SLC30A6 | ADORA2A 2680/4885ADORA3 1872/4885ADORA1 1601/4885 |
| US-20190328886-A1 | COMPOSITIONS COMPRISING A METAL SOURCE, DITHIOCARBAMATE AND CYCLODEXTRIN | PDIA5, SLC30A5, SLC30A6 | ADORA2A 2680/4885ADORA3 1872/4885ADORA1 1601/4885 |
| US-20100240680-A1 | Purine derivatives as a2a agonists | ADORA2A, ADORA1, ADORA3 | ADORA2A 1/4885ADORA3 3/4885ADORA1 2/4885 |
| US-20100240606-A1 | ASSOCIATIONS OF XANTHOGENATES AND CYCLODEXTRINS, AND THEIR USE | HLA-DRB1, CXCR3, ANTXR2 | ADORA2A 1652/4885ADORA3 649/4885ADORA1 331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.